"These results demonstrating that ganetespib potently
inhibits key signaling pathways involved in the growth and proliferation
of multiple forms of breast cancer are encouraging, and supportive of
the results presented earlier at this meeting showing single-agent,
anti-tumor activity in patients with breast cancer
who have progressed on or failed to respond to multiple prior
therapies," said Vojo Vukovic, M.D., Ph.D., Chief Medical Officer,
Synta.
Researchers conclude that, the combined preclinical and clinical results create a
strong rationale for advancing ganetespib development in both
HER2-positive and triple-negative breast cancer.
More : http://phoenix.corporate-ir.net/phoenix.zhtml?c=147988&p=irol-newsArticle&ID=1638540&highlight=
